Borui Biopharmaceuticals (Suzhou) Co., Ltd. is a biopharmaceutical company that mainly engages in the R&D, production and sales of innovative drugs. The company's core products include: 1) Recombinant Human Coagulation Factor VIII for Injection; 2) Recombinant Human Coagulation Factor IX for Injection; 3) Human Serum Albumin for Injection; 4) Human Immunoglobulin Injection.
This 464-page document contains Borui Biopharmaceuticals (Suzhou) Co., Ltd.'s detailed responses to the first round of inquiry letters from the Shanghai Stock Exchange concerning its IPO application on the Sci-Tech Innovation Board (STAR Market). Prepared with sponsor Minsheng Securities, the response addresses 49 questions across seven sections: equity structure and management basics, core technology, business operations, corporate governance and independence, financial accounting and management analysis, risk disclosures, and other matters. The excerpt shows detailed disclosure of new shareholders added in the prior year, including corporate shareholders Giant Sun and Guofa Qianhe, and partnership shareholders such as Sequoia Zhisheng, Hongpeng Investment, and Longmen Investment, with their equity structures and general partner information. This manual is written in Chinese.
The new corporate shareholders are Giant Sun Investments HK Limited and Guofa Qianhe Investment Co., Ltd.
Giant Sun is 100% owned by HL Partners II L.P.
The new partnership shareholders are Sequoia Zhisheng, Hongpeng Investment, Longmen Investment, Jingcheng Gaojin, and Zhuhai Zhangshi.